Clinical features at presentation, @entity2467 , and @entity1722 overexpression as prognostic factors in elderly @entity1 with XXXX .

@entity1 @entity1353 @entity2 @entity1149 @entity2467 @entity151 @entity1722
UNASSIGNED: 9636 Purpose: To determine the clinical predictors of survival and significance of @entity2467 and @entity1722 overexpression as prognostic markers in elderly males (age =/>65 years) with @entity2 ( @entity2 ). METHODS: After approval from the institutional review board, a retrospective chart review was performed to obtain demographic/clinical data on elderly males with a biopsy-proven @entity2 . @entity2467 and @entity1722 overexpression was also assessed using immunohistochemical techniques (IHC). RESULTS: 64 elderly males (mean age: 73.75 years; range: 65-87 years) were included in our study. 12/64 @entity1 (18.75%) had @entity151 ( @entity151 ) and 48 (75%) had @entity1149 ( @entity1149 ). 4 @entity1 (6.25%) refused diagnostic biopsies. The most common diagnostic procedures were CT-guided biopsy (n=38, 59.37%) and transbronchial biopsy (n=12, 18.75%). Of the 64 @entity1 studied, 24 (37.5%) presented with cough, 16 (25%) as an incidental finding and 8 (12.5%) with @entity1353 . Cox regression analysis revealed that @entity1 with @entity1353 at presentation had a 4.25 greater odds (95% CI 1.8-10, p=0.01) of early demise as compared with cough. With increasing performance status (from ECOG 0 to 4), the hazards of dying increased by 1.27 times the previous level (p=0.005). Interestingly, of the 12 @entity1 with @entity151 , 4 (33.3%) revealed @entity2467 overexpression, while none of the @entity1149 specimens revealed overexpression. Also, after adjusting for confounding variables, @entity2467 overexpression was associated with a significant survival advantage (p=0.018) in @entity151 , using the Log rank test. In contrast, presence of @entity1722 /neu identified in 4 @entity1 with @entity151 (33.3%) and 9 @entity1149 @entity1 (18.75%) had an insignificant effect on survival (p=0.87) in elderly males with @entity2 . CONCLUSIONS: Elderly males with @entity2 represent a select subgroup with characteristic clinical and pathologic features. @entity1722 overexpression seen in @entity1149 and @entity151 lacks prognostic significance in elderly males. Interestingly, however, @entity2467 overexpression, seen in    30% of the @entity151 cohort seems to confer a survival advantage. Further larger studies are needed to validate our findings. No significant financial relationships to disclose.
